An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium 177Lu vipivotide tetraxetan AAA617 versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen PSMA positive Oligometastatic Prostate Cancer OMPC

Brief Summary

Type:
Prostate

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05939414

Study #:
STUDY00160696

Start Date:
Nov 18, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05939414

View Complete Trial Details & Eligibility at ClinicalTrials.gov